China likely to approve BioNTech's COVID-19 vaccine by July - WSJ
FILE PHOTO: Syringes are seen in front of a displayed Biontech logo in this illustration taken November 10, 2020. REUTERS/Dado Ruvic/Illustration
(Reuters) -China is planning to authorize the COVID-19 vaccine developed by Germany's BioNTech SE by July, the Wall Street Journal reported on Friday, citing people familiar with the matter.
If approved, it would become the first foreign COVID-19 vaccine to be authorized in the country.
Chinese officials are reviewing clinical-trial data for the vaccine and are expected to authorize it for domestic use within the next 10 weeks, the report said.
BioNTech said in a statement that it does not speculate on timings of approvals.
The National Health Commission of China and Shanghai Fosun Pharmaceutical Group Co Ltd, which signed a potential supply deal with the German drugmaker in August for the vaccine, did not immediately respond to Reuters requests for comment. (https://reut.rs/2Q8psHJ)
The vaccine, developed in collaboration with Pfizer Inc, is already approved in several countries, including the United States, the United Kingdom and Israel.
U.S.-listed shares of BioNTech were up 3.3% at $145.4 on Friday.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Aditya Soni)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- US regulators mulling bid to limit bonuses for Wall Street execs, WSJ reports
- Chad air force chief orders US to halt activities at army base, letter shows
- Netflix Q1 earnings top estimates on blowout subscriber growth
Create E-mail Alert Related Categories
General News, ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!